Biogen pays $700mn to gain 49.9% share in Samsung Bioepis

By Catherine Sturman
Biopharmaceutical company Biogen has announced its decision to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2...

Biopharmaceutical company Biogen has announced its decision to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2012 by Samsung BioLogics Co., Ltd and Biogen. 

Under the terms of the 2012 joint venture agreement, Biogen will pay Samsung BioLogics approximately $700 million, increasing its ownership from approximately 5.4% to approximately 49.9%.  The completion of this share purchase is subject to certain regulatory closing conditions and is expected to close in the second half of 2018.  

Through the deal, the company will gain greater revenue in shares from Bioepis’ pharmaceutical products across Europe and the US.

“We are very pleased with the progress made to date at Samsung Bioepis and believe exercising this option is an opportunity to create meaningful value for shareholders,” said Michel Vounatsos, Chief Executive Officer at Biogen.

See also

“This option allows us to increase our ownership share in a leading biosimilar company at what we believe are attractive terms.  We look forward to building an important relationship with Samsung BioLogics.”

Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, it has a leading portfolio to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia.

This is on top of providing treatments for multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology.

Biogen also manufactures and commercialises biosimilars of advanced biologics, with products such as TNF inhibitor Remicade becoming approved in the US, in partnership with Merck & Co.

In the first quarter of 2018, biosimilars contributed $128 million in revenue to Biogen, a 93% increase over the same period last year, FiercePharma reported.

Share

Featured Articles

WHO Health Chatbot Built on 'Humanised' GenAI

World Health Organisation's GenAI digital health tool is built using ‘AI humanisation’ tech & designed to ease burden on health workers & educate on health

Costco Weight-Loss Drugs Move Highlights US AOM Growth

Costco move to partner with online healthcare provider Sesame to provide members with weight-loss drugs including Wegovy signals US anti-obesity boom

AstraZeneca Company Profile, as CEO Soriot Lands pay Deal

As it's announced AstraZeneca's CEO Pascal Soriot's package could rise by as much as US$24mn we explore the history of the UK's most valuable business

US Academic Medical Centres 'Struggling' says McKinsey

Hospitals

J&J Community Initiatives Tackle US Healthcare Chasm

Medical Devices & Pharma

PitchBook: Healthcare Private Equity Deals see Decline

Health Insurance & Finance